EGAM 2013: Videos of the presentations are available for viewing
14 Mar 2013
Thursday 7 March 2013
Opening remarks & Positioning the EORTC in the changing clinical research landscape – R. Stupp
SPECTAcolor, an EORTC initiative – S. Tejpar
OncoTrack: Precision medicine for colon cancer driven by genomics and systems biology – D. Henderson
The EORTC brain metastasis platform – W. Wick and M. Preusser
Emerging opportunities for drug development with radiation oncology – V. Grégoire
Integration of pharmacogenomics in clinical research – U. McDermott (Sanger Institute)
Friday 8 March 2013
New challenges for industry and new approaches to partnerships between industry and EORTC – M. Chlebus (EFPIA)
The changing landscape of drug development – S. Arlington (PwC)
Role of academia in the changing landscape: the regulator’s point of view – F. Pignatti (EMA)
Long term follow up studies : the Children’s Leukemia Group experience – C. Piette
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023